Summary
Small cell lung cancer (SCLC) accounts for 15 % of all lung tumors and represents an invasive neuroendocrine malignancy with poor survival rates. This cancer is highly prevalent in smokers and characterized by inactivation of p53 and retinoblastoma. First in vitro expansion of circulating tumor cells (CTCs) of SCLC patients allowed for investigation of the cell biology of tumor dissemination. In the suggested CTC SCLC model, the primary tumor attracts and educates tumor-promoting and immunosuppressive macrophages which in turn arm CTCs to spread and generate distal lesions. Preexisting inflammatory processes associated with chronic obstructive pulmonary disease (COPD) seem to potentiate the subsequent activity of tumor-associated macrophages (TAM). Activation of signal transducer and activator of transcription 3 (STAT3) and expression of chitinase-3-like 1/YKL-40 in SCLC CTCs seems to be associated with drug resistance. In conclusion, inflammation-associated generation of invasive and chemoresistant CTCs most likely explains the characteristic features of SCLC, namely early dissemination and rapid failure of chemotherapy.
Zusammenfassung
Das kleinzelliges Lungenkarzinom (SCLC) ist für 15 % der Lungenkarzinome verantwortlich und stellt eine aggressiv wachsende und invasive neuroendokrine maligne Erkrankung dar, die mit niedrigen Überlebensarten verbunden ist. Dieses Karzinom weist eine hohe Inzidenz bei Rauchern auf und ist vor allem durch die Inaktivierung von p53 und Retinoblastom-Gen charakterisiert. Die erstmalige in vitro Kultur von zirkulierenden Tumorzellen (CTCs) von SCLC Patienten ermöglichte die Untersuchung der Zellbiologie der Tumordissemination. Bei dem vorgeschlagenen Modell der SCLC CTCs rekrutiert der Tumor Makrophagen mit einem wachstumsfördernden und immunsuppressiven Phänotyp, der wiederum CTCs hervorbringt, die invasiv Fernmetastasen setzen. Bereits bestehende Entzündungsprozesse durch chronische obstruktive pulmonäre Erkrankung (COPD) scheinen die nachfolgende Aktivität der tumorassoziierten Makrophagen (TAM) zu potenzieren. Die Aktivierung von STAT3 und Chitinase-3-like-1/YKL-40 in den CTCs führt wahrscheinlich zur Chemoresistenz. Zusammenfassend führt die mit Entzündungen verbundene Entwicklung invasiver und chemoresistenter CTCs zu den typischen Charakteristika des kleinzelligen Lungenkarzinoms, nämlich früher Metastasierung und frühem Versagen der Chemotherapie und damit verweist dieses Modell des SCLC auf neue therapeutische Angriffspunkte.
Similar content being viewed by others
References
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664–72. doi:10.1002/cncr.29098.
Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244–55. doi:10.1158/1078 – 0432.CCR-14-2958.
Jiménez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14(9):1035–9. doi:10.1093/ntr/nts001.
Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184–90. doi:10.1038/nature08629.
Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol. 2014;41(1):133–42. doi:10.1053/j.seminoncol.2013.12.015.
Coleman MP, Allemani C. Cancer: the elephant in the room. Lancet. 2015;385(9973):1047–8. doi:10.1016/S0140-6736(15)60571-2.
Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257. doi:10.1038/cddis.2013.428.
Asai N, Ohkuni Y, Kaneko N, et al. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol. 2014;6(2):69–82. doi:10.1177/1758834013517413.
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54. doi:10.3978/j.issn.2218–6751.2014.05.01.
Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6. doi:10.1038/ng.2405.
Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51.
Pietanza MC, Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet. 2012;44(10):1074–5. doi:10.1038/ng.2415.
Ross JS, Wang K, Elkadi OR, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol. 2014;67(9):772–6.
Rolfo C, Castiglia M, Hong D, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014;1846(2):539–46. doi:10.1016/j.bbcan.2014.10.001.
Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung. 2015;193(3):451–2. doi:10.1007/s00408-015-9725-7.
Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014;12(1):3–13. doi:10.1158/1541–7786.MCR-13-0539.
Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol. 2001;14(7):767–90.
Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121–34. doi:10.1016/j.cell.2012.08.024.
Proctor RN. The cigarette catastrophe continues. Lancet. 2015;385(9972):938–9.
Lubin JH, Alavanja MC, Caporaso N, et al. Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol. 2007;166(4):479–89.
Muttarak R, Steiber N, Gallus S. Smoking ban in Austria: a long overdue step but still a lot to be done. Lancet. 2015;385(9972):941–2.
Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin. 2014;24(3):257–66. doi:10.1016/j.thorsurg.2014.04.001.
Hensing T, Chawla A, Batra R, et al. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014;799:85–117. doi:10.1007/978-1-4614-8778-45.
Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. doi:10.1016/j.ccm.2013.10.004.
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–51. doi:10.1016/S0140-6736(11)60968-9.
Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101(8):554–9. doi:10.1093/jnci/djp023.
Vlahos R, Bozinovski S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol. 2014;5:435. doi:10.3389/fimmu.2014.00435.
Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm. 2013;2013:413735. doi:10.1155/2013/413735.
Shaykhiev R, Krause A, Salit J, et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol. 2009;183(4):2867–83. doi:10.4049/jimmunol.0900473.
Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012;106(3):319–28. doi:10.1016/j.rmed.2011.11.003.
Churg A, Dai J, Tai H, Xie C, et al. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med. 2002;166(6):849–54.
Létuvé S, Kozhich A, Humbles A, et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol. 2010;176(2):638–49. doi:10.2353/ajpath.2010.090455.
Gwyer Findlay E, Hussell T. Macrophage-mediated inflammation and disease: a focus on the lung. Mediators Inflamm. 2012;2012:140937. doi:10.1155/2012/140937.
Cho SJ, Weiden MD, Lee CG. Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and COPD. Allergy Asthma Immunol Res. 2015;7(1):14–21. doi:10.4168/aair.2015.7.1.14.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401–6.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
Samadi AK, Bilsland A, Georgakilas AG. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol. 2015. doi:10.1016/j.semcancer.2015.03.006. (pii: S1044-579×(15)00021-8)
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. doi:10.1016/j.cell.2010.01.025.
Walser T, Cui X, Yanagawa J, Lee JM, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811–5. doi:10.1513/pats.200809-100TH.
Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med. 2008;14(10):1023–4. doi:10.1038/nm1008-1023.
Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer. 2013;13(4):233–45. doi:10.1038/nrc3477.
Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med. 1986;105(4):503–7.
Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology. 2011;16(7):1047–55. doi:10.1111/j.1440–1843.2011.02019.x.
Takiguchi Y, Sekine I, Iwasawa S, et al. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol. 2014;5(4):660–6. doi:10.5306/wjco.v5.i4.660.
Milara J, Cortijo J. Tobacco, inflammation, and respiratory tract cancer. Curr Pharm Des. 2012;18(26):3901–38.
Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011;81(4):265–84. doi:10.1159/000324601.
Cilli A, Ozkaynak C, Onur R, et al. Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients. Acta Radiol. 2007;48(4):405–11.
Heuvers ME, Wisnivesky J, Stricker BH, et al. Generalizability of results from the National Lung Screening Trial. Eur J Epidemiol. 2012;27(9):669–72. doi:10.1007/s10654-012-9720-8.
Sekine Y, Hata A, Koh E, et al. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment. Gen Thorac Cardiovasc Surg. 2014;62(7):415–21. doi:10.1007/s11748-014-0386-x.
Tang X, Liu D, Shishodia S, et al. NF-kappaB is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006;107(11):2637–46.
Li Z, Guo Y, Jiang H, et al. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 2014;14:276. doi:10.1186/1471-2407-14-276.
Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845(2):136–54. doi:10.1016/j.bbcan.2013.12.005.
Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831–52.
Chen YT, Feng B, Chen LB. Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev. 2012;13(8):3577–81.
López-González A, Diz P, et al. The role of anthracyclines in small cell lung cancer. Ann Transl Med. 2013;1(1):5. doi:10.3978/j.issn.2305–5839.2013.01.05.
Murray N. Treatment of small cell lung cancer: the state of the art. Lung Cancer. 1997;17(1):S75–S89.
Rossi A, Maio M D, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8. doi:10.1200/JCO.2011.40.4905.
O’Brien ME, Ciuleanu TE, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–7.
Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds213.
Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol. 2013;8(5):587–98. doi:10.1097/JTO.0b013e318286cf88.
Sgambato A, Casaluce F, Maione P, et al. Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother. 2013;14(15):2019–31. doi:10.1517/14656566.2013.823401.
Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother. 2014;15(16):2385–96. doi:10.1517/14656566.2014.957180.
William WN Jr, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol. 2011;8(10):611–9. doi:10.1038/nrclinonc.2011.90.
Verhelst K, Verstrepen L, Carpentier I, et al. IkB kinase e (IKKe): a therapeutic target in inflammation and cancer. Biochem Pharmacol. 2013;85(7):873–80. doi:10.1016/j.bcp.2013.01.007.
Erstad DJ, Cusack JC Jr. Targeting the NF-κB pathway in cancer therapy. Surg Oncol Clin N Am. 2013;22(4):705-46. doi: 10.1016/j.soc.2013.06.011.
Spitzner M, Ebner R, Wolff HA, et al. STAT3: a novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 2014;6(4):1986–2011. doi:10.3390/cancers6041986.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734.
Kennedy BC, Showers CR, Anderson DE, et al. Tumor-associated macrophages in glioma: friend or foe? J Oncol. 2013;2013:486912. doi:10.1155/2013/486912.
Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res. 2008;6(5):675–84. doi:10.1158/1541 – 7786.MCR-07-2180.
Yu H, Lee H, Herrmann A, Buettner R, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–46. doi:10.1038/nrc3818.
Li Y, Du H, Qin Y, et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007;67(18):8494–503.
Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2015. doi:10.1038/onc.2015.150.
Singh SK, Bhardwaj R, Wilczynska KM, et al. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem. 2011;286(46):39893–903. doi:10.1074/jbc.M111.257451.
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23. doi:10.1373/clinchem.2014.222679.
Board RE, Williams VS, Knight L, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci. 2008;1137:98–107. doi:10.1196/annals.1448.020.
Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75:892–901. doi:10.1158/0008-5472.CAN-14-2613.
Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20. doi:10.1126/science.1253533.
Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res. 2015;4(3):287-91. doi:10.3978/j.issn.2218–6751.2015.04.04.
Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897–903. doi:10.1038/nm.3600.
Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99–105. doi:10.1007/s12026-013-8459-y.
Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48(2):223–31.
Iwamoto FM, Hormigo A. Unveiling YKL-40, from serum marker to target therapy in glioblastoma. Front Oncol. 2014;4:90. doi:10.3389/fonc.2014.00090.
Ji RC. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci. 2012;69(6):897–914. doi:10.1007/s00018-011-0848-6.
Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133 + cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74(5):1554–65. doi:10.1158/0008-5472.CAN-13-1541.
Hamilton G, Olszewski U. Chemotherapy-induced enrichment of cancer stem cells in lung cancer. J Bioanal Biomed. 2013;S9:003. doi:10.4172/1948-593X.S9-003.
Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624–31. doi:10.1016/j.ygyno.2014.02.038.
Sherry MM, Reeves A, Wu JK, et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27(10):2383–92. doi:10.1002/stem.185.
Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195–205. doi:10.1111/j.1365–2249.2011.04515.x.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hamilton, G., Rath, B. Smoking, inflammation and small cell lung cancer: recent developments. Wien Med Wochenschr 165, 379–386 (2015). https://doi.org/10.1007/s10354-015-0381-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-015-0381-6